PL3788045T3 - Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania - Google Patents
Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystaniaInfo
- Publication number
- PL3788045T3 PL3788045T3 PL19724662.2T PL19724662T PL3788045T3 PL 3788045 T3 PL3788045 T3 PL 3788045T3 PL 19724662 T PL19724662 T PL 19724662T PL 3788045 T3 PL3788045 T3 PL 3788045T3
- Authority
- PL
- Poland
- Prior art keywords
- making
- methods
- same
- inhibitory compounds
- rip1
- Prior art date
Links
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 title 1
- 101100301091 Mus musculus Ralbp1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862666452P | 2018-05-03 | 2018-05-03 | |
PCT/US2019/030473 WO2019213445A1 (en) | 2018-05-03 | 2019-05-02 | Rip1 inhibitory compounds and methods for making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3788045T3 true PL3788045T3 (pl) | 2023-10-09 |
Family
ID=66554488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19724662.2T PL3788045T3 (pl) | 2018-05-03 | 2019-05-02 | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
Country Status (35)
Country | Link |
---|---|
US (2) | US10975064B2 (pl) |
EP (1) | EP3788045B1 (pl) |
JP (1) | JP7379467B2 (pl) |
KR (1) | KR20210006407A (pl) |
CN (1) | CN112384510A (pl) |
AU (1) | AU2019262142A1 (pl) |
BR (1) | BR112020022423A2 (pl) |
CA (1) | CA3099018A1 (pl) |
CL (1) | CL2020002840A1 (pl) |
CO (1) | CO2020015153A2 (pl) |
CR (1) | CR20200582A (pl) |
CY (1) | CY1126152T1 (pl) |
DK (1) | DK3788045T3 (pl) |
DO (1) | DOP2020000197A (pl) |
EA (1) | EA202092581A1 (pl) |
EC (1) | ECSP20077518A (pl) |
ES (1) | ES2947446T3 (pl) |
FI (1) | FI3788045T3 (pl) |
HR (1) | HRP20230909T1 (pl) |
HU (1) | HUE062277T2 (pl) |
IL (1) | IL278416B2 (pl) |
JO (1) | JOP20200277A1 (pl) |
LT (1) | LT3788045T (pl) |
MA (1) | MA52492B1 (pl) |
MD (1) | MD3788045T2 (pl) |
MX (1) | MX2020011622A (pl) |
PE (1) | PE20210414A1 (pl) |
PH (1) | PH12020551848A1 (pl) |
PL (1) | PL3788045T3 (pl) |
PT (1) | PT3788045T (pl) |
RS (1) | RS64418B1 (pl) |
SG (1) | SG11202010913PA (pl) |
SI (1) | SI3788045T1 (pl) |
WO (1) | WO2019213445A1 (pl) |
ZA (1) | ZA202007487B (pl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202010913PA (en) | 2018-05-03 | 2020-12-30 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
HUE063896T2 (hu) | 2018-05-03 | 2024-02-28 | Rigel Pharmaceuticals Inc | RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása |
WO2021046437A1 (en) | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
PE20221628A1 (es) | 2019-09-06 | 2022-10-19 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos |
WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
CA3155259A1 (en) | 2019-09-27 | 2021-04-01 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
KR20220079919A (ko) | 2019-11-07 | 2022-06-14 | 리겔 파마슈티칼스, 인크. | 헤테로시클릭 rip1 억제 화합물 |
JP2023502514A (ja) * | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤 |
AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
CN115867557A (zh) * | 2021-05-14 | 2023-03-28 | 中国医药研究开发中心有限公司 | 氮杂卓类稠环化合物及其医药用途 |
CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
WO2023076133A1 (en) * | 2021-10-27 | 2023-05-04 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
WO2023119210A1 (ko) * | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
ES2055280T3 (es) | 1989-12-04 | 1994-08-16 | Searle & Co | Sistema monocapa para la administracion transdermica de farmacos. |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
WO1993011938A1 (en) | 1991-12-18 | 1993-06-24 | Minnesota Mining And Manufacturing Company | Multilayered barrier structures |
ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
EP2192838A4 (en) | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
TWI637951B (zh) * | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
US20170266199A1 (en) * | 2014-08-21 | 2017-09-21 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
KR20170117472A (ko) | 2015-02-13 | 2017-10-23 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | (S)-5-벤질-N-(5-메틸-4-옥소-2,3,4,5-테트라히드로벤조[b][1,4]옥사제핀-3-일)-4H-1,2,4-트리아졸-3-카르복사미드의 결정질 형태 |
TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
PL3362449T3 (pl) | 2015-10-13 | 2021-12-13 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową |
CN108431004B (zh) | 2015-10-23 | 2021-02-12 | 武田药品工业株式会社 | 杂环化合物 |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
CR20180413A (es) * | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ. ホフマン-ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
BR112019017738A2 (pt) | 2017-02-27 | 2020-04-07 | Glaxosmithkline Ip Dev Ltd | combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto |
SG11202010913PA (en) | 2018-05-03 | 2020-12-30 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
HUE063896T2 (hu) | 2018-05-03 | 2024-02-28 | Rigel Pharmaceuticals Inc | RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása |
KR20210024574A (ko) | 2018-06-26 | 2021-03-05 | 상하이 인스티튜트 오브 오가닉 케미스트리, 차이니즈 아카데미 오브 사이언시스 | 세포 괴사 억제제 및 이의 제조 방법과 용도 |
JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Rip1キナーゼを阻害する複素環状アミド及びその使用 |
PE20221628A1 (es) | 2019-09-06 | 2022-10-19 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos |
WO2021046437A1 (en) | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/en active Active
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/en active Application Filing
- 2019-05-02 JO JOP/2020/0277A patent/JOP20200277A1/ar unknown
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 KR KR1020207034544A patent/KR20210006407A/ko unknown
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 CN CN201980045150.5A patent/CN112384510A/zh active Pending
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 AU AU2019262142A patent/AU2019262142A1/en active Pending
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 CA CA3099018A patent/CA3099018A1/en active Pending
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
-
2020
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
-
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
-
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202108603B (en) | Rip1 inhibitory compounds and methods for making and using the same | |
IL291033A (en) | rip1 inhibitory compounds and methods for their preparation and use | |
ZA202007487B (en) | Rip1 inhibitory compounds and methods for making and using the same | |
IL290781A (en) | rip1 inhibitory compounds and methods for their preparation and use | |
EP3746124A4 (en) | COMPOUNDS AND USES THEREOF | |
PT3594199T (pt) | 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação | |
EP3899293A4 (en) | LOCK NUT | |
IL277502A (en) | Compounds and uses for them | |
SG11202009138QA (en) | Silicon-terminated organo-metal compounds and processes for preparing the same | |
SG11202009175RA (en) | Silicon-terminated organo-metal compounds and processes for preparing the same | |
EP3853216A4 (en) | PYRIDINYL SUBSTITUTE COMPOUNDS AND THEIR USES | |
IL283309A (en) | rip1 inhibitors | |
IL279483A (en) | Cyanotriazole compounds and their uses | |
EP3724933A4 (en) | SUPRAL CONDUCTING COMPOUNDS AND METHOD FOR PRODUCING THEREOF | |
EP3743635A4 (en) | ANTI-KICKBACK LOCK | |
GB201917427D0 (en) | The flylead | |
GB201916822D0 (en) | The degravitator | |
ZA201906782B (en) | Mulcher | |
GB201904750D0 (en) | The dehydrometer | |
GB201902293D0 (en) | The hangit | |
GB201808686D0 (en) | The dogtooth | |
AU2018902788A0 (en) | 2018-05-25 6d | |
AU2018903548A0 (en) | Substituted-pyridinyl compounds and uses thereof | |
GB201800634D0 (en) | The Tasteaire |